Sellas Life Sciences stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech. In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new 52-week high ts2.tech. Big investors are piling in: BlackRock disclosed a 5.4% stake in SLS on Oct. 18 ts2.tech, and other funds like Vanguard and Marshall Wace added millions of shares in Q2 quiverquant.com. On the drug-development front, Sellas’s lead AML immunotherapy is in a Phase 3 AML trial, which recently passed an interim safety review ir.sellaslifesciences.com; SLS’s CDK9 inhibitor reported 44% response in a Phase 2 relapsed AML trial ir.sellaslifesciences.com and just showed statistically significant survival gains in a rare T-cell leukemia model ts2.tech ir.sellaslifesciences.com. The company will hold a virtual R&D Day on Oct. 29, 2025 to update investors on these AML programs ts2.tech, and final REGAL results are expected by late 2025 – potential near-term catalysts. Analysts are optimistic: Maxim Group reiterated a “Buy” and $7.00 12-month price target ts2.tech, and the consensus target implies ~220% upside ts2.tech investing.com. Sellas ended Q2 2025 with ~$25M cash on hand ts2.tech and raised another $23.6M through warrant exercises in Sept. 2025 ts2.tech to fund its trials. Overall,
